hero section gradient
3 handpicked stocks

Made in the UAE

The UAE is transforming from an oil-dependent economy into a diverse innovation hub. These carefully selected stocks represent companies at the forefront of this exciting growth story. Join this journey of economic transformation with promising investment potential.

Author avatar

Han Tan | Market Analyst

Published on May 4

Your Basket's Financial Footprint

Interpretation of the basket's market capitalisation and actionable investor takeaways.

Key Takeaways for Investors:
  • Large-cap dominance tends to reduce volatility, offering stability and closer tracking of broad-market moves.
  • Treat this basket as a core, diversified portfolio anchor rather than a speculative, high-risk growth position.
  • Likely steady, long-term appreciation rather than explosive short-term gains; growth usually moderate and gradual.
Total Market Cap
  • YALA: $949.36M

  • SWVL: $30.69M

  • Other

About This Group of Stocks

1

Our Expert Thinking

The UAE is diversifying beyond oil into technology, media, and industrial sectors. This collection focuses on innovative companies that showcase the UAE's economic transformation and strategic position as a global business hub connecting East and West.

2

What You Need to Know

These stocks represent the UAE's growing reputation for business-friendly policies, ranking as the easiest country to do business in the Middle East. The country's ambitious vision to become a global innovation center creates a unique investment opportunity in this rapidly developing market.

3

Why These Stocks

Our analysts selected these companies for their strong growth potential within the UAE's expanding economy. From social networking platforms to energy infrastructure, these businesses demonstrate the diverse investment opportunities emerging in this dynamic Arabian market.

Why You'll Want to Watch These Stocks

🚀

Riding the Growth Wave

The UAE's economy is transforming at an impressive pace, with companies like Yalla Group already showing 11% year-on-year growth in 2022. These stocks could be your ticket to this expanding market.

🌐

The Hub Advantage

The UAE's strategic position connecting East and West creates unique business opportunities. These companies are leveraging this advantage in technology, media, and energy sectors.

💼

Business-Friendly Ecosystem

The UAE ranks among the top 20 easiest places to do business globally. This favorable environment helps companies grow faster with fewer obstacles, potentially accelerating your investment returns.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions